论文部分内容阅读
本文采用~(125)Ⅰ标记甲氨蝶呤明胶微球(MTX—ms)。然后经大白鼠肝动脉灌注。作为MTX—ms动脉内化疗栓塞治疗肝癌的前期研究。于灌注后不同时间分别测定各主要脏器(心、肝、睥、肺和肾)的放射剂量分布,间接说明肝动脉灌注后MTX—ms在体内的分布。结果在一周的观察期内肝脏的总放射剂量明显高于其它脏器,占绝对优势,且下降缓慢。其它脏器的总放射剂量甚低或很快降低。作者对实验结果及其临床意义进行了讨论,认为MTX—ms具有末梢栓塞作用,可作为化疗栓塞剂用于肝癌的治疗。
This article uses ~ (125) I labeled methotrexate gelatin microspheres (MTX-ms). Then the rats were perfused with hepatic artery. As a preliminary study of MTX-ms arterial chemoembolization in the treatment of liver cancer. The radiation dose distributions of major organs (heart, liver, sputum, lung and kidney) were measured at different times after perfusion, which indirectly demonstrated the distribution of MTX-ms in the body after hepatic artery perfusion. Results During the one-week observation period, the total radiation dose of liver was significantly higher than other organs, accounting for an absolute advantage, and the decline was slow. The total radiation dose of other organs is very low or decreases rapidly. The author discussed the experimental results and their clinical significance, and concluded that MTX-ms has a peripheral embolism and can be used as a chemoembolization agent for the treatment of liver cancer.